S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
ASX:HMD

HeraMED Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume98,572 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive HMD News and Ratings via Email

Sign-up to receive the latest news and ratings for HeraMED and its competitors with MarketBeat's FREE daily newsletter.


About HeraMED

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is based in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$24,575.00
Book Value
A$0.01 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












HeraMED (ASX:HMD) Frequently Asked Questions

What stocks does MarketBeat like better than HeraMED?

Wall Street analysts have given HeraMED a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HeraMED wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are HeraMED's key executives?

HeraMED's management team includes the following people:
  • Mr. David Groberman, Co-Founder, CEO & Exec. Director
  • Mr. Tal Slonim, Co-Founder, COO & Exec. Director
  • Ms. Sivan Sadan, Chief Financial Officer
  • Mr. Michael Nenner, Chief Technology Officer
  • Henry Jordan, Head of Investor Relations
  • Mr. Ariel Laden, VP of Marketing
  • Dr. Josef Tovbin, Chief Medical Officer
  • Mr. Jonathan Hart B.Com., L.L.B., Company Sec.

What is HeraMED's stock symbol?

HeraMED trades on the ASX under the ticker symbol "HMD."

How much money does HeraMED make?

HeraMED has a market capitalization of $0.00 and generates $24,575.00 in revenue each year.

What is HeraMED's official website?

The official website for HeraMED is www.hera-med.com.

How can I contact HeraMED?

The company can be reached via phone at 61 8 6189 1155.


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.